Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study
- PMID: 33815819
- PMCID: PMC7802431
- DOI: 10.2144/fsoa-2020-0203
Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study
Abstract
The Italian municipality of Ariano Irpino (Avellino, Campania, Italy) was locked down by the regional authorities from March until April 2020 after several citizens tested positive for SARS coronavirus 2 (SARS-CoV-2). A serological mass screening campaign targeting the Ariano Irpino population using the Roche Cobas Elecsys anti-SARS-CoV-2 assay was organized by the Zoo-Prophylactic Institute of Southern Italy (Portici, Italy) and conducted in cooperation with the Local Health Unit (Azienda Sanitaria Locale - ASL - Avellino, Avellino, Italy), the Department of Public Health of University Federico II (Naples, Italy) and Department of Health Services of Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital (Naples, Italy) in May 2020. A total of 13,218 asymptomatic individuals were reviewed in this analysis. A total of 738 citizens tested positive for anti-SARS-CoV-2 antibodies (398 females, 340 males). The overall prevalence in the sample was 5.6% (95% CI: 5.2-6.0). Among seropositive citizens, 101 cases tested positive on RT-PCR (0.76% of the overall population). Among citizens aged 14-18, 18-65 and >65 years, the seroprevalence was equal to 6.1 (95% CI: 4.1-8.7), 5.6 (95% CI: 5.1-6.1) and 4% (95% CI: 3.3-4.8), respectively. In the pediatric cohort (<14 years old), seroprevalence was 13% (95% CI: 10.2-16.2). A serological-based screening strategy could be a cost-effective public health intervention to tackle the COVID-19 pandemic.
Keywords: Ariano Irpino; COVID-19; SARS-CoV-2; epidemiology.
© 2021 Carlo Buonerba.
Conflict of interest statement
Financial & competing interests disclosure C Buonerba is a member of the editorial board of Future Science OA. The authors recognize the following funding: POR FESR CAMPANIA 2014-2020- O.S. 1.3 - AZIONE 1.3.1. DG 10. – PROGETTO “Studio di Sorveglianza Sanitaria del virus SARS-CoV-2 responsabile della pandemia da COVID-19 nella popolazione ad alto rischio o esposta a contatto diretto con pazienti positivi” –CUP C75I20000060002, approved by the Federico II Ethics Committee (n. 141/20) - “GENCOVID – Studio di Sorveglianza Sanitaria del virus SARS-CoV-2 responsabile della pandemia da COVID-19 nella popolazione ad alto rischio o esposta a contatto diretto con pazienti positivi” – Protocollo Studio Clinico Studio SPEM – Covid19 – GENCOVID. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Figures
Similar articles
-
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up.Front Public Health. 2021 Dec 17;9:801609. doi: 10.3389/fpubh.2021.801609. eCollection 2021. Front Public Health. 2021. PMID: 34976939 Free PMC article.
-
First Description of Serological Evidence for SARS-CoV-2 in Lactating Cows.Animals (Basel). 2022 Jun 4;12(11):1459. doi: 10.3390/ani12111459. Animals (Basel). 2022. PMID: 35681922 Free PMC article.
-
SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.Microbiol Spectr. 2021 Oct 31;9(2):e0039121. doi: 10.1128/Spectrum.00391-21. Epub 2021 Sep 29. Microbiol Spectr. 2021. PMID: 34585976 Free PMC article.
-
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.Clin Microbiol Infect. 2021 Mar;27(3):331-340. doi: 10.1016/j.cmi.2020.10.020. Epub 2020 Oct 24. Clin Microbiol Infect. 2021. PMID: 33228974 Free PMC article.
-
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.PLoS One. 2021 Jun 23;16(6):e0252617. doi: 10.1371/journal.pone.0252617. eCollection 2021. PLoS One. 2021. PMID: 34161316 Free PMC article.
Cited by
-
Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.PLoS One. 2021 May 27;16(5):e0252235. doi: 10.1371/journal.pone.0252235. eCollection 2021. PLoS One. 2021. PMID: 34043706 Free PMC article.
-
No detection of SARS-CoV-2 in animals exposed to infected keepers: results of a COVID-19 surveillance program.Future Sci OA. 2021 Apr 20;7(7):FSO711. doi: 10.2144/fsoa-2021-0038. eCollection 2021 Aug. Future Sci OA. 2021. PMID: 34254029 Free PMC article.
-
Prevalence of SARS-CoV-2 Antibodies in Kosovo-Wide Population-Based Seroepidemiological Study.Influenza Other Respir Viruses. 2024 Sep;18(9):e70004. doi: 10.1111/irv.70004. Influenza Other Respir Viruses. 2024. PMID: 39225019 Free PMC article.
-
SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, Italy.Viruses. 2022 Jun 30;14(7):1441. doi: 10.3390/v14071441. Viruses. 2022. PMID: 35891420 Free PMC article.
-
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up.Front Public Health. 2021 Dec 17;9:801609. doi: 10.3389/fpubh.2021.801609. eCollection 2021. Front Public Health. 2021. PMID: 34976939 Free PMC article.
References
-
- WHO Coronavirus Disease (COVID-19) Dashboard. Accessed (2020). https://covid19.who.int/
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous